Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

633 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.
Gagno S, D'Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E, Montico M, Biason P, Cecchin E, Iacono D, Russo S, Cinausero M, Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R, Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P, Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G, Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM, Clerico M, Bonura S, Saggia C, Innocenti F, Toffoli G. Gagno S, et al. Among authors: serra p. Clin Breast Cancer. 2019 Apr;19(2):137-145.e4. doi: 10.1016/j.clbc.2018.11.009. Epub 2018 Nov 24. Clin Breast Cancer. 2019. PMID: 30584056 Free article.
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A. Amadori D, et al. Among authors: serra p. Breast Cancer Res Treat. 2011 Feb;125(3):775-84. doi: 10.1007/s10549-010-1257-5. Epub 2010 Dec 4. Breast Cancer Res Treat. 2011. PMID: 21132360 Free article. Clinical Trial.
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Amadori D, Milandri C, Comella G, Saracchini S, Salvagni S, Barone C, Bordonaro R, Gebbia V, Barbato A, Serra P, Gattuso D, Nanni O, Baconnet B, Gasparini G. Amadori D, et al. Among authors: serra p. Eur J Cancer. 2011 Sep;47(14):2091-8. doi: 10.1016/j.ejca.2011.05.005. Epub 2011 Jun 12. Eur J Cancer. 2011. PMID: 21665463 Clinical Trial.
Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E, Conteduca V, Andreis D, Massa I, Melegari E, Sarti S, Cecconetto L, Schirone A, Bravaccini S, Serra P, Fedeli A, Maltoni R, Amadori D, De Giorgi U, Rocca A. Pietri E, et al. Among authors: serra p. Endocr Relat Cancer. 2016 Oct;23(10):R485-98. doi: 10.1530/ERC-16-0190. Epub 2016 Aug 15. Endocr Relat Cancer. 2016. PMID: 27528625 Review.
Sorafenib for the treatment of breast cancer.
Bronte G, Andreis D, Bravaccini S, Maltoni R, Cecconetto L, Schirone A, Farolfi A, Fedeli A, Serra P, Donati C, Amadori D, Rocca A. Bronte G, et al. Among authors: serra p. Expert Opin Pharmacother. 2017 Apr;18(6):621-630. doi: 10.1080/14656566.2017.1309024. Epub 2017 Apr 7. Expert Opin Pharmacother. 2017. PMID: 28335647 Review.
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, Gianni L, Rosetti F, Amaducci L, Cavanna L, Foca F, Sarti S, Serra P, Valmorri L, Bruzzi P, Corradengo D, Gennari A; MYME investigators. Nanni O, et al. Among authors: serra p. Breast Cancer Res Treat. 2019 Apr;174(2):433-442. doi: 10.1007/s10549-018-05070-2. Epub 2018 Dec 7. Breast Cancer Res Treat. 2019. PMID: 30536182 Free article. Clinical Trial.
Explaining the aggressiveness of breast cancer in sub-Saharan African patients.
Bravaccini S, Bucchi L, Puccetti M, Ravaioli S, Tumedei MM, Serra P, Masini C, Kahima J, Masalu N, Amadori D. Bravaccini S, et al. Among authors: serra p. J Clin Pathol. 2019 Oct;72(10):723-724. doi: 10.1136/jclinpath-2019-206071. Epub 2019 Aug 13. J Clin Pathol. 2019. PMID: 31409610 No abstract available.
633 results